Among the 21 patients who presented a discrepancy in the HER2 status between the primary CRC and the metastasis, four (19.1%) had metachronous metastasis and 17 (80.9%) had synchronous metastasis. This evidence concerns the gene ERBB2 and colorectal carcinoma.